Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

MLA

Koo, Dong-Hoe, et al. “Long-Term Outcomes of Tyrosine Kinase Inhibitor Discontinuation in Patients with Metastatic Renal Cell Carcinoma.” Cancer Chemotherapy & Pharmacology, vol. 77, no. 2, Feb. 2016, pp. 339–47. EBSCOhost, https://doi.org/10.1007/s00280-015-2942-1.

APA

Koo, D.-H., Park, I., Ahn, J.-H., Lee, D.-H., You, D., Jeong, I.-G., Song, C., Hong, B., Hong, J., Ahn, H., Lee, J.-L., & Hong, J. H. (2016). Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy & Pharmacology, 77(2), 339–347. https://doi.org/10.1007/s00280-015-2942-1

Chicago

Koo, Dong-Hoe, Inkeun Park, Jin-Hee Ahn, Dae-Ho Lee, Dalsan You, In-Gab Jeong, Cheryn Song, et al. 2016. “Long-Term Outcomes of Tyrosine Kinase Inhibitor Discontinuation in Patients with Metastatic Renal Cell Carcinoma.” Cancer Chemotherapy & Pharmacology 77 (2): 339–47. doi:10.1007/s00280-015-2942-1.